<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499183</url>
  </required_header>
  <id_info>
    <org_study_id>NL74418.081.20</org_study_id>
    <nct_id>NCT04499183</nct_id>
  </id_info>
  <brief_title>Fiber Fermentation, and Short Chain Fatty Acid Kinetics and Utilization Inside the Gut and Systemic Circulation</brief_title>
  <official_title>A Feasibility Study on Fiber Fermentation, and Short Chain Fatty Acid Kinetics and Utilization Inside the Gut and Systemic Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nowadays there is a strong interest in optimising human health through manipulation of&#xD;
      non-digestible carbohydrates (NDC). NDC can be used as substrates by gut microbiota, which&#xD;
      results in NDC degradation, production of fermentation products, such as short-chain fatty&#xD;
      acids (SCFA), and a shift in microbiome composition and activity. It is hypothesized that&#xD;
      SCFAs mediate parts of the beneficial effects of NDC. In mice, the influx of SCFA into the&#xD;
      host correlated strongly with improvements of markers of the metabolic syndrome, in contrast&#xD;
      to the concentrations of SCFA in the proximal colon. Therefore, the influx of short chain&#xD;
      fatty acids (SCFA) into the body may be of high importance in improving metabolism. There is&#xD;
      a need for more studies in humans to trace the life course of SCFA and their regulatory role&#xD;
      in human metabolism. To study this inner world of bacterial products in humans, we will use a&#xD;
      nasal-intestine catheter that can be used for delivery of components and sampling chyme in&#xD;
      the proximal colon. Before the proposed methodology can be applied in a large intervention&#xD;
      study, a small scale feasibility study needs to be performed that addresses colonic placement&#xD;
      of the nasal-intestine cathether and colonic sampling of regular and NDC-enriched chyme&#xD;
      samples. We will investigate the acute fermentation of fructo- and galacto-oligosaccharides&#xD;
      in the proximal colon. Moreover, we will deliver 13C-labelled SCFA via a naso-intestinal&#xD;
      catheter to quantify the fluxes of SCFA production, interconversion and uptake by the host. A&#xD;
      small-scale, 7-day parallel feasibility trial, N=5 subjects will receive GOS/FOS supplements&#xD;
      (mix 1:1 ratio, 15 gram/day), and N=5 other subjects will receive placebo supplements&#xD;
      (isocaloric maltodextrin, 12 gram/day). At the last day of the supplementation period, the&#xD;
      catheter will be placed, and afterwards participants stay maximum 5 hours in the hospital, to&#xD;
      ensure progression of the nose-intestine catheter. After an overnight fast, subjects will&#xD;
      visit the hospital again for measurements. Subjects will consume a NDC bolus (200 mL tap&#xD;
      water, 5 gram fructo-oligosaccharides, 5 gram galacto-oligosaccharides, non-absorbable marker&#xD;
      (PEG-4000). Afterwards, they are not allowed to eat for 6.5 hours. Isotopically 13C-labelled&#xD;
      SCFAs will be delivered in the proximal colon. Blood and colonic luminal samples, breath&#xD;
      samples, faeces and urine will be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of carbohydrates</measure>
    <time_frame>Between 0 and 400 minutes</time_frame>
    <description>mono-, di-, tri-, oligo- and polysaccharides in the intestinal lumen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative microbiota composition and metabolites</measure>
    <time_frame>Between 0 and 400 minutes</time_frame>
    <description>Microbiota and metabolites inside the intestine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of plasma metabolites</measure>
    <time_frame>Between 0 and 400 minutes</time_frame>
    <description>organic acids, amino acids, glucose, cholesterol, fatty acids and bile acids in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Catheter placement in the colon</measure>
    <time_frame>After 1 week</time_frame>
    <description>To show placement of a naso-intestinal catheter in the proximal colon.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of colon sample (mL)</measure>
    <time_frame>Between 0 and 400 minutes</time_frame>
    <description>To check whether enough material for analysis is obtained if the catheter system takes samples in the proximal colon of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of SCFAs</measure>
    <time_frame>Between 0 and 400 minutes</time_frame>
    <description>(13C isotopic) enrichments of SCFAs inside intestinal lumen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of urine metabolites</measure>
    <time_frame>After 0 and 120 minutes</time_frame>
    <description>hippurate, di- en tri-methylamine, acetaldehydes, taurine, glycine, glucuronic acid conjugates, and bile acid profiles (conjugates)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires about (dis)comfort of study procedures</measure>
    <time_frame>After 1 week</time_frame>
    <description>Questions about study procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative microbiota composition and metabolite concentrations</measure>
    <time_frame>After 1 week</time_frame>
    <description>Microbiota and metabolome in faeces</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentrations of non-digestible markers</measure>
    <time_frame>Between 0 and 400 minutes</time_frame>
    <description>TiO2 and PEG-4000 inside the intestine</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Dietary Fiber</condition>
  <arm_group>
    <arm_group_label>non-digestible carbohydrates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fructo- and galacto-oligosaccharides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fructo- and galacto-oligosaccharides</intervention_name>
    <description>15 gram/day fructo- and galacto-oligosaccharides</description>
    <arm_group_label>non-digestible carbohydrates</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>FOS and GOS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  Age 18-60yrs&#xD;
&#xD;
          -  BMI between 18.5 and 30 kg/m2&#xD;
&#xD;
          -  Regular bowel movement (defaecation on average once a day)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Having a history of medical or surgical events that, in the opinion of the&#xD;
             Investigator, may either put the subject at risk because of participation in the&#xD;
             study, or influence the results of the study (e.g. diabetes, cardiovascular disease,&#xD;
             gastrointestinal disease, renal failure, cancer, infectious disease, nose/throat).&#xD;
&#xD;
          -  Having a history of surgical events of the gastro-intestinal tract (e.g. bariatric&#xD;
             surgery/gastric bypass surgery)&#xD;
&#xD;
          -  Presence of swallowing disorder&#xD;
&#xD;
          -  Use of any prescribed or non-prescribed medication (other than paracetamol) including&#xD;
             antacids, analgesics, and herbal remedies during the three (3) weeks prior to study&#xD;
             start.&#xD;
&#xD;
          -  Being lactose intolerant&#xD;
&#xD;
          -  Follows a vegan diet&#xD;
&#xD;
          -  Use of antibiotics within 3 months of starting the study or planned during the study&#xD;
&#xD;
          -  Use of pro- or prebiotics (e.g. galacto-oligosaccharides, fructo-oligosaccharides)&#xD;
&#xD;
          -  Constipation/infrequent bowel movement (less than 3 times defaecation per week)&#xD;
&#xD;
          -  Abuse of drugs/alcohol (alcohol: &gt;4 consumptions/day or &gt;21 consumptions/week)&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Having diarrhoea within 1 month prior to the study start&#xD;
&#xD;
          -  Personnel of Wageningen University, Division of Human Nutrition, their partner and&#xD;
             their first and second degree relatives&#xD;
&#xD;
          -  Participation in another biomedical study or other research from the Division of Human&#xD;
             Nutrition&#xD;
&#xD;
          -  Not willing to be exposed to fluoroscopy&#xD;
&#xD;
          -  Having a hemoglobin of &lt;8.5 mmol/L&#xD;
&#xD;
          -  Having blood vessels that are too difficult for inserting a cannula&#xD;
&#xD;
          -  Not having a general practitioner&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MARA VAN TRIJP</last_name>
    <phone>0317 484 067</phone>
    <email>mara.vantrijp@wur.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guido Hooiveld</last_name>
    <email>guido.hooiveld@wur.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wageningen University and Research</name>
      <address>
        <city>Wageningen</city>
        <zip>6708 WE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara van Trijp, MSc</last_name>
      <email>mara.vantrijp@wur.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

